Medpace Holdings, Inc. Common Stock
MEDPMedpace Holdings, Inc. is a global contract research organization (CRO) that provides comprehensive clinical development services to the pharmaceutical, biotechnology, and medical device industries. Founded in 1992 and headquartered in Cincinnati, Ohio, Medpace specializes in conducting clinical trials across various therapeutic areas, offering expertise in regulatory affairs, data management, and project management to support drug development and approval processes.
Company News
A class action lawsuit has been filed against Medpace Holdings, Inc. on behalf of shareholders for alleged securities fraud. The lawsuit was triggered after Medpace reported a book-to-bill ratio of 1.04 on February 9, 2026, significantly below company guidance, causing the stock to plunge 15.9% to $446.05 per share. The class period covers April ...
Rosen Law Firm is notifying investors about multiple securities class action lawsuits. The primary case involves Medpace Holdings, with a June 8, 2026 deadline for lead plaintiff claims. The lawsuit alleges Medpace made false statements about backlog cancellation rates and provided misleading growth projections. Additional class actions are menti...
A class action lawsuit has been filed against Medpace Holdings, Inc. alleging that company executives made materially false and misleading statements regarding the book-to-bill ratio during the period from April 22, 2025 to February 9, 2026. The complaint claims defendants portrayed an overly optimistic ratio of approximately 1.15 despite contrar...
Rosen Law Firm is urging investors who purchased Veritone, Inc. securities between October 14, 2025 and April 14, 2026 to join a class action lawsuit before the July 20, 2026 lead plaintiff deadline. The lawsuit alleges that Veritone made false statements about its financial performance, inaccurately recorded revenue and costs, overstated assets,...
Rosen Law Firm is notifying investors in Medpace Holdings, Upstart Holdings, and Babcock & Wilcox Enterprises of securities class action lawsuits. The firm alleges that Medpace made false statements about backlog cancellation rates and provided misleading growth projections. Investors with losses exceeding $100,000 are encouraged to secure counse...
